Navigation Links
Kyowa Hakko Kirin Announces Development Policy for Anti-Parkinson's Disease Drug KW-6002 (Istradefylline)
Date:1/14/2009

TOKYO, Jan. 15 /PRNewswire/ -- Kyowa Hakko Kirin Co., Ltd. (Chiyoda-ku, Tokyo Japan; President, Dr. Yuzuru Matsuda) announced on January 15 (Tokyo Time) that it has decided to continue the domestic development of its proprietary anti-Parkinson's disease drug KW-6002 (generic name: Istradefylline) and move it forward with a Phase 3 clinical trial in Japan.

KW-6002 has a novel mechanism of action that specifically antagonizes the adenosine A2A receptor. Kyowa Hakko Kirin initiated the clinical evaluation of KW-6002 in 1996, and conducted Phase 2 and 3 studies in the US and Europe to assess its efficacy and safety in Parkinson's disease patients who were experiencing wearing-off phenomenon*, a motor complication, while receiving Levodopa therapy alone or in combination with other anti-Parkinson's disease drugs. Based on the results of these studies, the new drug application (NDA) for registration of KW-6002 in the US was submitted to the Food and Drug Administration (FDA) in April 2007. On February 25, 2008, Kyowa received an action letter from the FDA. Subsequent to discussions with FDA, Kyowa decided to await the results of the ongoing Japanese phase 2b study of KW-6002 as adjunctive therapy to Levodopa, and then comprehensively examine and determine a path forward for KW-6002.

The results of the Phase 2b study in Japan have recently become available and demonstrate the efficacy of KW-6002 compared with placebo, warranting further clinical investigation in Japan.

For the development and commercialization of KW-6002 in overseas markets, is pursuing out-licensing opportunities.

We believe that KW-6002 will offer a new therapeutic option for Parkinson's disease and provide clinical benefit to patients suffering from wearing-off phenomenon and other symptoms.

* Parkinson's disease is a progressive neurodegenerative disorder which is characterized by motor symptoms such a
'/>"/>

SOURCE Kyowa Hakko Kirin Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
2. Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE Healthcare and Uppsala University
3. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
4. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
5. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
6. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
7. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
8. ProUroCare Medical Inc. Announces Pricing of Equity Offering
9. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
10. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
11. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Landauer, Inc. (NYSE: ... and environmental radiation measurement and monitoring, outsourced medical physics ... financial results for the fiscal third quarter 2014 after ... The Company will host a conference call ... a.m. Central Time (10 a.m. Eastern Time). Investors may ...
(Date:7/29/2014)... WASHINGTON , July 29, 2014 New ... in Medicare Part D by a projected $2.9 to ... by the actuarial firm Milliman released today by the ... Part D premiums could increase by as much as ... hepatitis C drugs, including Sovaldi and Olysio. ...
(Date:7/29/2014)... July 29, 2014 Numotion,s Board of Directors has ... will be the company,s new Chief Executive Officer. ... career at GE where he worked primarily for GE Healthcare ... to over $5 billion. His most recent position was as ... "I am thrilled to join Numotion," said Mike ...
Breaking Medicine Technology:Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Numotion Names Mike Swinford CEO 2
... 3, 2011 Nonin Medical, Inc., the inventor of ... a leader in noninvasive physiological monitoring, announced the worldwide ... Pulse Oximeter for medical monitoring manufacturers. ... wired pulse oximeter will provide a new level of ...
... Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR ) ... Senior Vice President of Research and Development, Cynthia Schwalm ... M.D., as Senior Vice President of Pharmacovigilance. These newly ... the Company prepares for the potential launch of its ...
Cached Medicine Technology:Nonin Medical Launches Low Power Xpod®, Model 3012LP, OEM Pulse Oximeter Globally 2Optimer Pharmaceuticals Expands Senior Management Team 2Optimer Pharmaceuticals Expands Senior Management Team 3Optimer Pharmaceuticals Expands Senior Management Team 4Optimer Pharmaceuticals Expands Senior Management Team 5
(Date:7/30/2014)... The Diabetes Daily Grind had its beginnings ... Ryan Fightmaster hope to gain attention for the website ... 26th of this year, Clour and Fightmaster started this ... diabetic life. By sharing stories on their lessons ... other diabetics will find ways to live with their ...
(Date:7/30/2014)... According to the Nasal Polyps Treatment Miracle book review recently ... people how to cure their nasal polyps permanently ... horrible truth about conventional treatments for nasal polyps. , ... will learn how to prevent symptoms related to nasal ... Nasal Polyps Treatment Miracle, as it is reviewed now by ...
(Date:7/30/2014)... The San Diego personal injury lawyers of The ... they are now offering free case reviews for individuals that ... , “Symptoms of asbestos exposure can take years to develop, ... years ago may just now be suffering from the ill ... Melinda J. Helbock A.P.C. “We want people to know that ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Nuanced Media, a ... announce the release of the Medical Web Design Trends of ... of research done across multiple agencies and the medical web ... are constantly changing as the industry grows. Therefore it is ... of ideas that consumers enjoy most. New trends are defined ...
(Date:7/29/2014)... 30, 2014 Saint Luke’s Medical ... awarded the Patient-Centered Medical Home 2011 Level 3 ... for Quality Assurance. Only one out of four ... Level 2, or Level 3 recognition. , Patients ... Medical Home report faster access to their doctors, ...
Breaking Medicine News(10 mins):Health News:Strangers Come Together to Form Diabetes Website: Real Messages of Hope and Inspiration 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:The Law Office of Melinda J. Helbock A.P.C. Offers Case Evaluations for Possible Asbestos Claims 2Health News:Nuanced Media Releases "Medical Web Design Trends of 2014" Article 2Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2
... of the disease among those vaccinated were no higher ... (HealthDay News) -- Rates of a rare neurodegenerative disease, ... last year were no higher than among the general ... syndrome were noted after widespread swine flu vaccination in ...
... April 13, 2010 Allergies have become a widespread ... are all increasingly prevalent. The reason? Excessive cleanliness is ... at the Universit de Montral Faculty of Medicine. ... pollution, processed foods, stress, tobacco use, etc. Yet our ...
... 2010) The human mouth is home to an estimated ... moist environment, along with hard tooth surfaces and soft tissues, ... of these bacteria are harmful and can form a film ... eventually more severe kinds of gum disease. Toothpaste ...
... ... features and prices of March special SEO offers, SEO-Peace.com management is pleased to extend its ... features to the client base. , ... Gurgaon, India (PRWEB) April 13, 2010 -- With SEO industry getting more and more ...
... , ... 1 out of every 6 men in the United States (1 in 3 in the ... against prostate cancer by registering for Little Red Door,s Unite 2 Fight Race Against Prostate ... Indianapolis, IN (PRWEB) ...
... with Williams syndrome have no social fear and appear ... 13 (HealthDay News) -- Children with a rare ... and with it, racial prejudice, a new study shows. ... the root cause of racial stereotyping. , French and ...
Cached Medicine News:Health News:Guillain-Barre Syndrome Very Rare After H1N1 Vaccine 2Health News:Guillain-Barre Syndrome Very Rare After H1N1 Vaccine 3Health News:Why are allergies increasing? 2Health News:Give dirty mouths a brush 2Health News:SEO-Peace.com Extends The March Special SEO Special Offers And Revise Many Services 2Health News:Registration Now Open for Little Red Door's Unite 2 Fight Race Against Prostate Cancer Saturday, July 10, 2010 2Health News:Kids With Rare Condition Lack Racial Prejudice 2
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Periosteal elevator #9, 18 cm, 7"....
Full curve periosteal elevator - cervical - sharp, round tip, length 184 mm (7 1/4")....
... The Frontier Anterior Deformity System ... Kass, Moss Miami, and Isola ... thoracoscopic procedures to deliver unsurpassed versatility, ... the highest level of versatility for ...
Medicine Products: